Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study

R. L.H. Bolhuis; C. H.J. Lamers; S. H. Goey; A. M.M. Eggermont; J. B.M.Z. Trimbos; G. Stoter; A. Lanzavecchia; E. Di Re; S. Miotti; F. Raspagliesi; L. Rivoltini; M. I. Colnaghi

Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study

R. L.H. Bolhuis
, C. H.J. Lamers
, S. H. Goey
, A. M.M. Eggermont
, J. B.M.Z. Trimbos
, G. Stoter
, A. Lanzavecchia
, E. Di Re
, S. Miotti
, F. Raspagliesi
, L. Rivoltini
, M. I. Colnaghi

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

116 Citaten (Scopus)

Samenvatting

A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.

Originele taal-2	Engels
Pagina's (van-tot)	78-81
Aantal pagina's	4
Tijdschrift	International Journal of Cancer
Nummer van het tijdschrift	SUPPL. 7
Status	Gepubliceerd - 1992
Extern gepubliceerd	Ja

Citeer dit

@article{a7d1e388ab8b46c8affe64701ab587b6,

title = "Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study",

abstract = "A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.",

author = "Bolhuis, \{R. L.H.\} and Lamers, \{C. H.J.\} and Goey, \{S. H.\} and Eggermont, \{A. M.M.\} and Trimbos, \{J. B.M.Z.\} and G. Stoter and A. Lanzavecchia and \{Di Re\}, E. and S. Miotti and F. Raspagliesi and L. Rivoltini and Colnaghi, \{M. I.\}",

year = "1992",

language = "English",

pages = "78--81",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "John Wiley and Sons Inc.",

number = "SUPPL. 7",

}

TY - JOUR

T1 - Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes

T2 - A multicenter study

AU - Bolhuis, R. L.H.

AU - Lamers, C. H.J.

AU - Goey, S. H.

AU - Eggermont, A. M.M.

AU - Trimbos, J. B.M.Z.

AU - Stoter, G.

AU - Lanzavecchia, A.

AU - Di Re, E.

AU - Miotti, S.

AU - Raspagliesi, F.

AU - Rivoltini, L.

AU - Colnaghi, M. I.

PY - 1992

Y1 - 1992

N2 - A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.

AB - A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), 1 stable disease (SD) and 1 progressive disease (PD). In the Italian study 3 CR, 1 PR, 1 SD and 2 PD were seen.

UR - https://www.scopus.com/pages/publications/0026494425

M3 - Article

C2 - 1428412

AN - SCOPUS:0026494425

SN - 0020-7136

SP - 78

EP - 81

JO - International Journal of Cancer

JF - International Journal of Cancer

IS - SUPPL. 7

ER -

Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: A multicenter study

Samenvatting

Vingerafdruk

Citeer dit